Amarin Corp Plc (AMRN)

Trade AMRN now with
1/7/2020 6:03:18 AM Amarin Reiterates 2020 Net Total Revenue Guidance At $650 Mln-$700 Mln
1/2/2020 6:05:08 AM Amarin Says VASCEPA Approved In Canada To Reduce Risk Of Cardiovascular Events
8/8/2019 6:01:00 PM Amarin Does Not Expect FDA To Take Action On Vascepa SNDA By Prior Announced Sept. 28, 2019 PDUFA Goal Date
7/17/2019 5:35:47 PM Amarin Says FDA Not Informed Whether It Plans To Hold An AdCom Meeting To Discuss SNDA For Vascepa
7/2/2019 6:07:07 AM Amarin Boosts 2019 Guidance For Revenue To Range Of $380 Mln-$420 Mln
5/29/2019 6:19:58 AM Amarin: FDA Grants Priority Review For Vascepa SNDA Seeking Cardiovascular Risk Reduction Indication
2/27/2019 5:06:15 AM Amarin Q4 GAAP Loss Per Share $0.11; Non-GAAP Loss Per Share $0.09
11/26/2018 9:00:24 PM Amarin Announces Pricing Of Underwritten Public Offering Of ADSs For Gross Proceeds Of About $200.0 Mln
11/1/2018 5:11:11 AM Amarin Corp Q3 GAAP Net Loss $24.5 Mln Or $0.08/Shr Vs Loss $10.8 Mln Or $0.04/shr Last Year